

Biogen Idec - BG-12: Next Oral MS Pill - Driving Valuations

<https://marketpublishers.com/r/B6C0D29C53CEN.html>

Date: July 2012

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: B6C0D29C53CEN

Abstracts

Biogen Idec (BIIB) is one of our top picks for 2012, as it promises growth on the strength of its marketed products and pipeline. 2Q12 earnings reiterate our thesis, as BIIB is poised to enrich its revenue stream and MS franchise in 2012/13 with the launch of oral BG-12 (Dimethyl fumarate, R). Clinical news flow from long-lasting blood Factors – rFactorVIII (PhIII, hemophilia A, partnered with Biovitrium) and rFactorIX (PhIII, hemophilia B) offer a competitive advantage and share of the Hemophilia market while success of Dexpramipexole (PhIII) in Amyotrophic Lateral Sclerosis (ALS) could fill in a... For further detail, please read our report released on 26th July, 2012, titled, “BG-12: Next Oral MS Pill – Driving Valuations”.

I would like to order

Product name: Biogen Idec - BG-12: Next Oral MS Pill - Driving Valuations

Product link: <https://marketpublishers.com/r/B6C0D29C53CEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B6C0D29C53CEN.html>